You have read all your free articles, to continue reading subscribe to read the rest of this content.
Ultimovacs has completed treatment of the second dose cohort in the Phase I TENDU trial. The study is designed to evaluate the company's Tetanus-Epitope Targeting (TET)-platform in patients with prostate cancer. Encouraging results The Drug Safety Monitoring Board (DSMB), a group of experts Already a subscriber Login You have read all your free…
The company has received feedback from the Regional Committees for Medical and Health Research Ethics (REK) in Norway with regard to the Clinical Trial Application (CTA) for the Archer-1 Phase 1b trial with Betalutin (177Lu-satetraxetan-lilotomab) in combination with rituximab in second-line follicuAlready a subscriber Login You have read all your…
On 10-11 October the 4th annual event Outsourcing in Clinical Trials Nordics will be returning to the capital of Denmark. The 2 day event last September saw over 150 delegates working on clinical trials from pharmaceutical, biotech and medical device companies come together to discuss the industrAlready a subscriber Login…
Regulatory approvals have been obtained for the first clinical study of ATOR-1015 and patient recruitment can now be initiated. ATOR-1015 is a wholly-owned drug candidate developed for tumor-directed immunotherapy. A first-in-human dose-escalation study The phase I study is a first-in-human dosAlready a subscriber Login You have read all your free…
